From Custom to On-Demand: Making TCR-Based Cell Therapies Commercially Scalable
- Changing the paradigm, from autologous to allogeneic, from single antigen to multiple activation mechanisms, from custom to on-demand
- Current opportunities and challenges of large-scale TCR-NK cells manufacturing
- Approaches to tackle cost-of-goods and increase patient access